Lipocalin muteins with binding affinity for LAG-3

US11168119B2 · kind B2 · utility

Assignee

• Pieris Pharmaceuticals GmbH · DE

Inventors

• Christine Rothe · Freising, DE
• Shane Olwill · Freising, DE
• Andrea Allersdorfer · Wolnzach, DE
• Timo Eichner · Freising, DE
• Rachida Siham Bel Aiba · Munich, DE
• Marina Pavlidou · Freising, DE

Key dates

• Filing date: Jan 18, 2018
• Grant date: Nov 9, 2021
• Expiry date: Jan 18, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/70503
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.